Oncology Ventures Closes Oversubscribed $62M Fund II to Back Cancer Care Infrastructure Startups
Capital showed up with a memory this time. Oncology Ventures just closed a $62M Fund II out of Austin, and you can feel the difference between money looking for returns and money that’s seen the problem up close.
Ben Freeberg didn’t design this from a whiteboard. He lived it. Stage IIIA cancer doesn’t leave room for theory, and 9 months of misdiagnosis tends to sharpen your view on where the system breaks. So Oncology Ventures leans into the unsexy layer most people ignore. Not drugs. Not devices. The plumbing. The data. The connective tissue that decides whether innovation actually reaches a patient or dies in a slide deck.
This Fund II came in oversubscribed, blowing past a $50M target with Texas Oncology anchoring the round. That’s not just a logo grab. That’s 550 physicians, 300 locations, and 250K+ patients a year sitting in the same room as your cap table. Add Moffitt Cancer Center, City of Hope, Atlantic Health, Cardinal Health, and Fred Hutch Cancer Center, and now you’re not pitching the market… you’re inside it. 1 in 3 U.S. cancer patients connected to your LP base is less “network” and more gravitational pull.
Behind the capital, the bench is deep. Jay Freeberg keeps the numbers honest as CFO. Nandita Kotwani brings operator-grade perspective from Memorial Sloan Kettering and Flatiron Health. Sebastian Rositano adds clinical depth shaped by the World Health Organization. Ethan Zohn brings the survivor’s lens you can’t fake. And around them, a circle that reads like a who’s who of oncology and healthcare: Dr. Karen Knudsen, Nancy Brown, Brad Hively, Dr. Lee Newcomer, Emily Melton, Carolyn Starrett, and Dr. Jeff Patton. Not decorative names. People who’ve built, scaled, and stress-tested this system from every angle.
The strategy stays disciplined. Seed-stage checks between $250K–$1.5M, backing companies that already have a pulse. Not science experiments. Real products, early traction, and a clear shot at fixing the mess between discovery and delivery. Early detection, care navigation, AI-driven treatment optimization, survivorship, workflow automation… the stuff that quietly determines whether outcomes improve or just headlines do.
Portfolio signals aren’t subtle either. Risa cutting $2M in annual costs at a single system. IgniteData giving 70 hours back per patient to research teams. Reimagine Care keeping 95% of symptom management out of the ER. Concr stretching survival curves in ways that make you reread the numbers twice.
Fund I closed at $32M. Fund II nearly doubles it to $62M. Total capital now at $94M, but the real multiplier is access. When your LPs double as validation partners, distribution channels, and clinical proving grounds, you compress timelines most startups never survive long enough to see.
Oncology Ventures isn’t betting on a single breakthrough. It’s underwriting the system that lets breakthroughs matter. And if you’ve ever watched healthcare move at the speed of paperwork, you already know… fixing the pipes might be the boldest play in the room.
